VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study

NCT06249555 · clinicaltrials.gov ↗

RECRUITING

Status

300

Enrollment

OTHER

Sponsor class

Conditions

Crohn's Disease

Interventions

DRUG: Vedolizumab (VDZ)
DRUG: Ustekinumab (UST)
DRUG: Risankizumab (RISA)
DRUG: Guselkumab (GUS)
DRUG: Mirikizumab (MIR)

Sponsor

Alimentiv Inc.

Collaborators

[object Object]